ストックスクリーナーアプリを入手
2.29
0.71%
-0.0164
前日終値:
$2.3064
開ける：
$2.31
24時間の取引高:
6.84M
Relative Volume:
0.68
時価総額：
$2.26B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-2.3608
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
-2.97%
1か月 パフォーマンス:
+6.51%
6か月 パフォーマンス:
-21.03%
1年 パフォーマンス:
-49.89%
1日の値動き範囲:
$2.2433
$2.32
1週間の範囲:
$2.06
$2.46
52週間の値動き範囲:
$1.83
$5.12
Immunitybio Inc Stock (IBRX) Company Profile
IBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.29 | 2.27B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio, Inc. (IBRX): A Bull Case Theory - Insider Monkey
Is ImmunityBio Inc. stock a smart buy before Fed meeting2025 Price Targets & Safe Entry Zone Tips - Newser
Will ImmunityBio Inc. (26CA) stock benefit from mergersJuly 2025 Price Swings & Breakout Confirmation Alerts - Newser
How ImmunityBio Inc. (26CA) stock responds to bond marketJuly 2025 Drop Watch & Intraday High Probability Alerts - Newser
Piper Sandler Remains a Buy on ImmunityBio (IBRX) - The Globe and Mail
Is ImmunityBio Inc. (26CA) stock undervalued at current priceWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
ImmunityBio (NASDAQ:IBRX) Trading Down 5.4%Should You Sell? - MarketBeat
Lawmakers Invited to FDA Meeting for Patrick Soon-Shiong’s Drug - Bloomberg.com
ImmunityBio (IBRX) Slashes 9% on Lack of Leads - Finviz
A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (NASDAQ:IBRX) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ImmunityBio Stock Rises Despite Financial Challenges - timothysykes.com
Can ImmunityBio Inc. (26CA) stock sustain free cash flowRisk Management & Reliable Volume Spike Trade Alerts - Newser
Geode Capital Management LLC Acquires 1,487,849 Shares of ImmunityBio, Inc. $IBRX - MarketBeat
Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility - Yahoo Finance
A Fresh Look at ImmunityBio (IBRX) Valuation After Recent Share Rally - Yahoo Finance
ImmunityBio (IBRX) Soars 10.8% Ahead of Health Conferences - Insider Monkey
ImmunityBio Skyrockets on Positive Trial Results and Sales Growth - StocksToTrade
ImmunityBio Boosts Outlook with Strong Revenue Growth and Clinical Advances - timothysykes.com
ImmunityBio’s Immunotherapy Focus Boosts Market Expectations - StocksToTrade
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances - timothysykes.com
Is ImmunityBio Inc. (IBRX) The Best US Stock To Buy Under $20? - Insider Monkey
10 Stocks Racking Up Big Gains - Insider Monkey
ImmunityBio Stock Boosted by Rising Demand for ANKTIVA and Positive Clinical Trials - StocksToTrade
ImmunityBio’s Strong Market Position Boosted by Recent Innovations - timothysykes.com
HEIGHTS CAPITAL MANAGEMENT, INC's ImmunityBio Inc(IBRX) Holding History - GuruFocus
ImmunityBio’s Clinical Advances and Sales Boost Highlight Market Optimism - StocksToTrade
ImmunityBio Stock (IBRX) Opinions on Q3 Revenue Growth - Quiver Quantitative
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's Why - MarketBeat
Some Confidence Is Lacking In ImmunityBio, Inc.'s (NASDAQ:IBRX) P/S - 富途牛牛
ImmunityBio’s Strategic Developments and Financial Growth Fuel Optimism - timothysykes.com
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning? - ts2.tech
Why ImmunityBio (IBRX) Is Up 13.5% After Strong Q3 Anktiva Revenue Surge Announced at Jefferies London - simplywall.st
ImmunityBio Stock Surges Amid Growing Demand and Clinical Success - StocksToTrade
ImmunityBio’s Remarkable Growth: Unpacking the Surge - StocksToTrade
ImmunityBio Explores Innovations in Cancer Treatment - timothysykes.com
ImmunityBio (IBRX) Stock Forecast and Price Target 2025 - MarketBeat
ImmunityBio (IBRX): Evaluating Valuation After Q3 Revenue Growth and Operational Improvements - simplywall.st
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know - AOL.com
What to know about Anktiva, the cancer drug that doesn’t use chemotherapy - NewsNation
How does nonchemotherapy cancer treatment Anktiva work? - NewsNation
Q3 2025 Contract Research Organization (CRO) Activity and Intel Report Featuring ICON, Astrazeneca, Akesobio, CSPPC Pharmaceutical, ImmunityBio, and Boryung - Yahoo Finance
H.C. Wainwright Asserts Buy Rating on Immunitybio Inc. (IBRX) as Net Loss Narrows on Robust Product Revenue - MSN
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
1.44%
0.91%
大文字化:
|
ボリューム (24 時間):